Upsher-Smith launches prenatal vitamin to relieve morning sickness
MAPLE GROVE, Minn. — Drug maker Upsher-Smith Labs has launched a prenatal vitamin designed to help relieve morning sickness, the company said Monday.
Upsher-Smith announced the launch of B-Nexa, which contains B vitamins and ginger to help calm morning sickness, known medically as nausea and vomiting of pregnancy, which affects 83% of pregnant women throughout the day, according to medical experts.
"B-Nexa is a new option in the prenatal nutrition market that has been designed to help calm nausea and vomiting of pregnancy, with vitamin B6 and ginger, while also providing women with essential folic acid," Upsher-Smith senior director of medical affairs Wesley Mark Todd said. "With the launch of B-Nexa, Upsher-Smith is pleased to have another opportunity to demonstrate our commitment to women’s prenatal health."
Four-legged family members can reap Rx benefits at Houston-area Kroger stores
HOUSTON — Pet medications now are available at all Kroger pharmacies in the Houston area, the company said.
Customers with four-legged family members now can pick up their pets’ prescriptions at the pharmacy counter. Popular medications, such as Frontline Plus and Rimadyl Chewables, are available, as well as $4 and $10 generic medications.
This offering, however, isn’t a first for the company. Kroger affiliate KPF Insurance Services partnered with PetFirst Healthcare to offer pet insurance underwritten by American Alternative Insurance Corp.
According to a recent survey conducted by Kroger, about 1-in-10 dog or cat owners is willing to spend more than $3,000 on medical procedures if it meant that their pet could be saved, while 61% of those surveyed said they would be willing to spend between $100 and $1,000 to save their pets’ life, and an additional 15% is comfortable spending between $1,000 and $3,000 for lifesaving medical care for their pet.
Novo Nordisk to open Type 1 diabetes research and development center
PRINCETON, N.J. — In an effort to take Type 1 diabetes research to the next level, Novo Nordisk is set to open a research and development center in Seattle.
The center, slated to open this summer, will combine basic research and early proof-of-concept trials under one umbrella, the drug maker said. Additionally, the center will be staffed by approximately 20 researchers who will be supported by corporate functions in the United States and Denmark.
"Novo Nordisk has been passionate about helping people fight diabetes since the company was founded, and it is part of our mission to Take type 1 diabetes research to the next level," said Mads Krogsgaard Thomsen, EVP and chief science officer at Novo Nordisk. "With the new Type 1 diabetes R&D center, we hope to accelerate the process of finding new, innovative ways of treating people with this disease. Our vision is to prevent, treat and ultimately cure diabetes."